Literature DB >> 23201928

Photon activation therapy of RG2 glioma carrying Fischer rats using stable thallium and monochromatic synchrotron radiation.

Crister Ceberg1, Bo-Anders Jönsson, Yolanda Prezado, Tobias Pommer, Henrietta Nittby, Elisabet Englund, Gustav Grafström, Anneli Edvardsson, Anna Stenvall, Susanne Strömblad, Karin Wingårdh, Bertil Persson, Hélène Elleaume, Bo Baldetorp, Leif G Salford, Sven-Erik Strand.   

Abstract

75 RG2 glioma-carrying Fischer rats were treated by photon activation therapy (PAT) with monochromatic synchrotron radiation and stable thallium. Three groups were treated with thallium in combination with radiation at different energy; immediately below and above the thallium K-edge, and at 50 keV. Three control groups were given irradiation only, thallium only, or no treatment at all. For animals receiving thallium in combination with radiation to 15 Gy at 50 keV, the median survival time was 30 days, which was 67% longer than for the untreated controls (p = 0.0020) and 36% longer than for the group treated with radiation alone (not significant). Treatment with thallium and radiation at the higher energy levels were not effective at the given absorbed dose and thallium concentration. In the groups treated at 50 keV and above the K-edge, several animals exhibited extensive and sometimes contra-lateral edema, neuronal death and frank tissue necrosis. No such marked changes were seen in the other groups. The results were discussed with reference to Monte Carlo calculated electron energy spectra and dose enhancement factors.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23201928     DOI: 10.1088/0031-9155/57/24/8377

Source DB:  PubMed          Journal:  Phys Med Biol        ISSN: 0031-9155            Impact factor:   3.609


  5 in total

1.  Keeping those telomeres short! an innovative intratumoral long-term drug delivery system.

Authors:  B H Laster; C Isaacson; E Perets; M Msamra; E Priel; J Kalef-Ezra; J Kost
Journal:  J Cancer Res Clin Oncol       Date:  2014-07-30       Impact factor: 4.553

Review 2.  Nanoparticles as Theranostic Vehicles in Experimental and Clinical Applications-Focus on Prostate and Breast Cancer.

Authors:  Jörgen Elgqvist
Journal:  Int J Mol Sci       Date:  2017-05-20       Impact factor: 5.923

3.  Mathematical modelling of the synergistic combination of radiotherapy and indoleamine-2,3-dioxygenase (IDO) inhibitory immunotherapy against glioblastoma.

Authors:  Arthur Chakwizira; Jonatan Ahlstedt; Henrietta Nittby Redebrandt; Crister Ceberg
Journal:  Br J Radiol       Date:  2018-05-17       Impact factor: 3.039

4.  Destruction of tumor mass by gadolinium-loaded nanoparticles irradiated with monochromatic X-rays: Implications for the Auger therapy.

Authors:  Kotaro Matsumoto; Hiroyuki Saitoh; Tan Le Hoang Doan; Ayumi Shiro; Keigo Nakai; Aoi Komatsu; Masahiko Tsujimoto; Ryo Yasuda; Tetsuya Kawachi; Toshiki Tajima; Fuyuhiko Tamanoi
Journal:  Sci Rep       Date:  2019-09-30       Impact factor: 4.379

5.  Iodine containing porous organosilica nanoparticles trigger tumor spheroids destruction upon monochromatic X-ray irradiation: DNA breaks and K-edge energy X-ray.

Authors:  Yuya Higashi; Kotaro Matsumoto; Hiroyuki Saitoh; Ayumi Shiro; Yue Ma; Mathilde Laird; Shanmugavel Chinnathambi; Albane Birault; Tan Le Hoang Doan; Ryo Yasuda; Toshiki Tajima; Tetsuya Kawachi; Fuyuhiko Tamanoi
Journal:  Sci Rep       Date:  2021-07-14       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.